R/R AML with IDH1 and IDH2 mutations have been treated with IDH1/2 inhibitors, the treatment with IDH1/2 inhibitors will continue even after reaching beneficial response if not moving to allo-SCT could be counted as maintenance therapy in some way. This evidence concerns the gene IDH2 and acute myeloid leukemia.